1 Le laboratoire Digestivelab de l`Université McGill

1
Le laboratoire Digestivelab de l’Université McGill est heureux de vous offrir un outil de
dosage de la calprotectine fécale pour vos patients. La calprotectine fécale est maintenant
établie comme étant un biomarqueur d’inflammation intestinale utile sur le plan clinique qui
permet de distinguer les maladies inflammatoires de l’intestin du syndrome du colon irritable
et de suivre l’évolution des maladies inflammatoires de l’intestin ainsi que la réponse au
traitement. Grâce à une généreuse commandite d’un de nos partenaires, nous pouvons vous
offrir cet outil diagnostique tout à fait gratuitement, incluant les frais d’expédition, pour
un temps limité. Si vous êtes intéressé, veuillez communiquer avec Anne Duhaime (514934-8304 ; [email protected]) pour obtenir de plus amples renseignements.
Avantages du dosage de la calprotectine fécale :
Non invasif
Plus précis que la mesure de la vitesse de sédimentation ou le dosage de la protéine
C réactive
Stable pendant 6 jours au réfrigérateur
Résultats rapides
Références :
1. Van Rheened PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected
inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
2. Sydora, M., Sydora, B. Fedorak, R. Validation of a point-of-care desk top device to quantitate fecal
calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohn’s and
Colitis Online 2011 (sous presse)
3. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue(R) rapid test for faecal calprotectin.
Ann Clin Biochem 2011 Sep 19.
4. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn'
s disease affecting the
small bowel and colon. Scand J Gastroenterol 2011 Jun;46(6):694-700. Publication électronique : 1er avril
2011.
5. Dolci A, Panteghini M, Comparative study of a new quantitative rapid test with an established ELISA
method for faecal calprotectin. Clin Chim Acta 2012 Jan 18;413-(1-2):350-1
6. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of
fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC
Gastroenterol. 2012 Jan 10;12(1):5. [Prépublication électronique]
1
The McGill Digestivelab is pleased to offer fecal calprotectin testing for your patients. Fecal
calprotectin has become established as a clinically useful biomarker for intestinal
inflammation (IBD vs IBS) as well as to follow IBD activity and response to therapy.
Thanks to a generous partnership between our lab and a corporate sponsor we can offer you
this diagnostic test free of charge, including shipping, for a limited time. If you are
interested please contact Anne Duhaime (514-934-8304; [email protected])
and she will provide you with more information.
Benefits of fecal calprotectin testing:
Non invasive
More accurate than ESR or CRP
Stable for 6 days when refrigerated
Rapid results
References:
1. Van Rheened PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected
inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
2. Sydora, M., Sydora, B. Fedorak, R. Validation of a point-of-care desk top device to quantitate fecal
calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. In press- J
Crohn’s and Colitis. Online 2011 (In Press)
3. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue(R) rapid test for faecal calprotectin.
Ann Clin Biochem 2011 Sep 19.;
4. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn'
s disease affecting the
small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. Epub 2011 Apr 1.
5. Dolci A, Panteghini M, Comparative study of a new quantitative rapid test with an established ELISA
method for faecal calprotectin.Clin Chim Acta. 2012 Jan 18;413-(1-2):350-1
6. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of
fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC
Gastroenterol. 2012 Jan 10;12(1):5. [Epub ahead of print]